Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study

Ryu Watanabe^{1

2}

Affiliations

¹ Department of Rheumatology, Osaki Citizen Hospital, Osaki.
² Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Comment

Ryu Watanabe. Rheumatology (Oxford). 2020.

. 2020 Sep 1;59(9):e46-e47.

doi: 10.1093/rheumatology/keaa253.

Ryu Watanabe^{1

2}

¹ Department of Rheumatology, Osaki Citizen Hospital, Osaki.
² Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan.

No abstract available

Comment in

Comment on: Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study: reply.
Nakaoka Y, Yamashita K, Yamakido S. Nakaoka Y, et al. Rheumatology (Oxford). 2020 Sep 1;59(9):e48-e49. doi: 10.1093/rheumatology/keaa255. Rheumatology (Oxford). 2020. PMID: 32594147 Free PMC article. No abstract available.

Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, Nishimoto N. Nakaoka Y, et al. Rheumatology (Oxford). 2020 Sep 1;59(9):2427-2434. doi: 10.1093/rheumatology/kez630. Rheumatology (Oxford). 2020. PMID: 31951279 Free PMC article. Clinical Trial.